Small Business Inovation Research

Estrigenix Appoints Patricia Scheller as Executive Chairwoman

MILWAUKEE (Dec. 5, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce Patricia Scheller as its executive chairwoman.    In this role, Scheller will be actively involved in Estrigenix’s business. She will chair the board of directors, act as an advisor to William Donaldson, <strong>Estrigenix Appoints Patricia Scheller as Executive Chairwoman</strong>

Estrigenix Therapeutics, Inc. presents at American Chemical Society’s Midwest Regional Meeting

MILWAUKEE (Oct. 19, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is presenting atthe Midwest Regional Meeting of the American Chemical Society in Iowa City, Iowa on Wednesday, October 19, 2022. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix is presenting an abstract entitled, “Discovery Estrigenix Therapeutics, Inc. presents at American Chemical Society’s Midwest Regional Meeting

Estrigenix Therapeutics, Inc. Awarded $300,000 Grant from the National Institute of Health

MILWAUKEE (Oct. 17, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, has been awarded a $300,000 National Institute of Health (NIH) Small Business Innovation Research (SBIR) Phase I grant. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce Estrigenix Therapeutics, Inc. Awarded $300,000 Grant from the National Institute of Health